Jardiance Shortage Update: What Patients Need to Know in 2026

The Latest on Jardiance Availability in 2026

If you rely on Jardiance (Empagliflozin) to manage type 2 diabetes, heart failure, or chronic kidney disease, you may have noticed it's been harder to find at your pharmacy lately. Hearing "we're out of stock" when you need your medication is alarming — and it raises the obvious question: is Jardiance in a drug shortage?

Here's what we know as of March 2026, and what you can do to protect your health.

Is Jardiance Still in Shortage?

As of March 2026, Jardiance is not listed on the FDA Drug Shortage Database or the ASHP (American Society of Health-System Pharmacists) drug shortage list. That means there is no official, nationwide shortage of Empagliflozin.

However, "no formal shortage" doesn't mean every pharmacy has it on the shelf. Many patients across the country have reported difficulty finding Jardiance at their usual pharmacy. These are intermittent stock-outs — temporary gaps at specific locations — rather than a systemic supply failure.

Why Is Jardiance Hard to Find?

Several factors are driving the availability challenges patients are experiencing:

Expanded FDA Indications

Jardiance was originally approved just for type 2 diabetes in 2014. Since then, it's gained FDA approvals for:

• Reducing cardiovascular death in adults with type 2 diabetes and cardiovascular disease (2016)
• Heart failure in adults, regardless of ejection fraction (2022-2023)
• Chronic kidney disease in adults at risk of progression (late 2025)

Each new indication has expanded the patient population. Millions more people now have a medical reason to take Jardiance, and demand has surged accordingly.

No Generic Available

Despite FDA approval of a generic Empagliflozin, patent protections have kept generic versions off U.S. pharmacy shelves. The earliest anticipated generic launch is sometime in 2026-2027. Until then, Boehringer Ingelheim's brand-name product is the sole source, creating a supply bottleneck.

Insurance Formulary Changes

At the start of 2026, many insurance plans updated their formularies. Plans that newly added Jardiance as a preferred brand saw a rush of new prescriptions. This created a temporary demand spike that some pharmacy distribution networks couldn't absorb immediately.

Growing Diabetes Prevalence

The CDC estimates that over 37 million Americans have diabetes, with type 2 accounting for 90-95% of cases. As the diabetes population grows, so does demand for effective treatments like Jardiance. Read more in our article about why Jardiance is so hard to find.

How Much Does Jardiance Cost in 2026?

Cost remains a significant barrier for many patients. Here's the current pricing landscape:

• List price: Approximately $629 per month (30-day supply) as set by Boehringer Ingelheim
• Average cash price without insurance: $550 to $830 depending on the pharmacy
• With commercial insurance: Copays typically range from $25 to $100 per month, depending on your plan's tier
• Medicare Part D: Most plans cover Jardiance; out-of-pocket costs vary by plan and phase (deductible, coverage gap, catastrophic)
• With manufacturer savings card: As low as $10/month for eligible commercially insured patients

If cost is a challenge, our guide on how to save money on Jardiance covers every option available.

New Options and Developments in 2026

There are several developments that could improve the situation this year:

Generic Empagliflozin on the Horizon

Multiple pharmaceutical companies have received FDA approval for generic Empagliflozin. Patent litigation is working through the courts, and industry analysts expect generic launches to begin in 2026 or early 2027. Once generics hit the market, prices could drop significantly and supply should improve.

CKD Indication Awareness

With the late-2025 FDA approval for chronic kidney disease, more nephrologists are prescribing Jardiance. While this increases demand in the short term, it also means more manufacturers are motivated to ensure adequate supply for this expanding market.

Combination Products

If the standalone Jardiance tablet isn't available, don't forget about combination products: Synjardy (Empagliflozin + Metformin), Synjardy XR (extended-release), Glyxambi (Empagliflozin + Linagliptin), and Trijardy XR (Empagliflozin + Linagliptin + Metformin). These contain the same active ingredient and may be available when the standalone tablet isn't.

How to Find Jardiance in Stock

Here's your action plan for getting Jardiance in 2026:

1. Use Medfinder to check real-time pharmacy availability near you
2. Try independent pharmacies — they often have access to multiple wholesalers
3. Ask your pharmacy to order it — special orders typically arrive within 1-2 business days
4. Consider mail-order pharmacy — 90-day supplies by mail tend to be more reliable
5. Talk to your doctor — they can help you find alternatives like Farxiga or Invokana if needed

For more tips, see our full guide on how to find Jardiance in stock near you.

Final Thoughts

Jardiance is not in a formal drug shortage, but availability challenges are real and frustrating. The combination of expanded indications, no generic alternative yet, and insurance changes has created a tighter supply. Stay proactive: check stock with Medfinder, keep your prescriber informed, and explore all your options. Your treatment is too important to skip.